Surgery pp 209-235 | Cite as

Diagnosis and Treatment of Infection

  • David L. Dunn


Over the span of recorded history, the occurrence of serious infection after injury has been the rule rather than the exception, with such sequelae of our interaction with the microbial world often resulting in death. For centuries, infection after traumatic wounding was considered a desirable outcome, as evidenced by the epithet “laudable pus,” which, once drained, was associated with wound healing in those patients who were able to survive both the inciting event and the ensuing infection. During the past century, the development and use of anesthesia, fluid resuscitation, blood transfusion, and hemodynamic monitoring were key advances that allowed surgical practitioners to carry out increasingly complex procedures. However, before the widespread application of aseptic surgical technique and the subsequent discovery and therapeutic use of antimicrobial agents, the evolution and performance of even routine surgical procedures was hindered by the frequent association with serious, often life-threatening infections.


Host Defense Necrotizing Fasciitis Intraabdominal Infection Sepsis Syndrome Catheter Infection 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Dunn DL. Autochthonous microflora of the gastrointestinal tract. Perspect Colon Rectal Surg 1990;2:105–119.Google Scholar
  2. 2.
    Dunn DL, Barke RA, Knight NB, Humphrey EW, Simmons RL. Role of resident macrophages, peripheral neutrophils, and translymphatic absorption in bacterial clearance from the peritoneal cavity. Infect Immun 1985;49:257–264.PubMedGoogle Scholar
  3. 3.
    Dunn DL, Simmons RL. Fibrin in peritonitis. III. The mechanism of bacterial trapping by polymerizing fibrin. Surgery (St. Louis) 1982;92:513–519.PubMedGoogle Scholar
  4. 4.
    Dunn DL, Meakins JL. Humoral immunity to infection and the complement system. In: Howard RJ, Simmons RL, eds. Surgical Infectious Diseases, 3rd ed. Norwalk: Appleton and Lange, 1995:295–312.Google Scholar
  5. 5.
    Fong Y, Moldawer LL, Shires GT, Lowry SF. The biologic characteristics of cytokines and their implication in surgical injury. Surg Gynecol Obstet 1990;170:363–378.PubMedGoogle Scholar
  6. 6.
    Hack C, Aarden LA, Thijs LG. Role of cytokines in sepsis. Adv Immunol 1997;66:101–195.PubMedCrossRefGoogle Scholar
  7. 7.
    Battafarano RJ, Burd RS, Kurrelmeyer KM, Ratz CA, Dunn DL. Inhibition of splenic macrophage tumor necrosis factor-α secretion in vivo by antilipopolysaccharide monoclonal antibodies. Arch Surg 1994;129:179–186.PubMedGoogle Scholar
  8. 8.
    Banner DW, D’Arcy A, Janes W, et al. Crystal structure of the soluble human 55 kDa TNF receptor-human TNF beta complex: implications for TNF receptor activation. Cell 1993;73:431–445.PubMedCrossRefGoogle Scholar
  9. 9.
    Giri JG, Wells J, Dower SK, et al. Elevated levels of shed type II IL-1 receptor in sepsis: potential role for type II receptor in regulation of IL-1 responses. J Immunol 1994;153:5802–5809.PubMedGoogle Scholar
  10. 10.
    Porteu F, Nathan CF. Shedding of tumor necrosis factor receptors by activated human neutrophils. J Exp Med 1990;172:599–607.PubMedCrossRefGoogle Scholar
  11. 11.
    Pruitt J, Copeland E, Moldawer L. Interleukin-1 and interleukin-1 antagonism in sepsis systemic inflammatory response syndrome and septic shock. Shock 1995;3:235–251.PubMedCrossRefGoogle Scholar
  12. 12.
    Aderka D. The potential biological and clinical significance of the soluble tumor necrosis factor receptors. Cytokine Growth Factor Rev 1996;7:231–240.PubMedCrossRefGoogle Scholar
  13. 13.
    Goldie AS, Fearon KC, Ross JA, et al. Natural cytokine antagonists and endogenous antiendotoxin core antibodies in sepsis syndrome. The Sepsis Intervention Group. JAMA 1995;274:172–177.PubMedCrossRefGoogle Scholar
  14. 14.
    Dunn DL, Barke RA, Ewald DC, Simmons RL. Macrophages and translymphatic absorption represent the first line of host defense of the peritoneal cavity. Arch Surg 1987;122:105–110.PubMedGoogle Scholar
  15. 15.
    Barie PS, Dellinger EP, Dougherty SH, Fink MP. Assessment of hepatitis B virus immunization status among North American surgeons. Arch Surg 1994;129:27–31.PubMedGoogle Scholar
  16. 16.
    Updated U.S. public health service guidelines for management of occupational exposure to HBV, HCV, and HIV and recommendations for postexposure prophylaxis. Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. Centers for Disease Control and Prevention. MMWR Morb Mortal Wkly Rep 2001;50:1–42.Google Scholar
  17. 17.
    Panlilio AL, Cardo DM, Grohskopf LA, et al. Updated U.S. public health service guidelines for the management of occupational exposure to HIV and recommendations for postexposure prophylaxis: provisional public health service recommendation for chemoprophylaxis after occupational exposure to HIV. MMWR Morb Mortal Wkly Rep 2005;54:1–17.Google Scholar
  18. 18.
    Sawyer MS, Dunn DL. Appropriate use of antimicrobial agents. Nine principles. Postgrad Med 1991;90:115–122.PubMedGoogle Scholar
  19. 19.
    O’Grady NP, Barie PS, Bartlett JG, et al. Practice guidelines for evaluating new fever in critically ill adult patients. Task Force of the Society of Critical Care Medicine and the Infectious Diseases Society of America. Clin Infect Diseases 1998;26:1042–1059.CrossRefGoogle Scholar
  20. 20.
    National Nosocomial Infections Surveillance (NNIS) System report, data summary from October 1986–April 1998, issued June 1998. Am J Infect Control 1998;26:522–533.Google Scholar
  21. 21.
    Tambyah PA, Halvorson KT, Maki DG. A prospective study of pathogenesis of catheter-associated urinary tract infections. Mayo Clin Proc 1999;74:131–136.PubMedCrossRefGoogle Scholar
  22. 22.
    Heyland D, Cook DJ, Griffith L, Keenan SP, Brun-Buisson C. The attributable morbidity and mortality of ventilator-associated pneumonia in the critically ill patient. The Canadian Critical Trials Group. Am J Respir Crit Care Med 1999;159:1249–1256.PubMedGoogle Scholar
  23. 23.
    Bowton DL. Nosocomial pneumonia in the ICU—year 2000 and beyond. Chest 1999;115:28S–33S.PubMedCrossRefGoogle Scholar
  24. 24.
    Burke JF. Preventing bacterial infection by coordinating antibiotic and host activity: a time dependent activity. South Med J 1977;1:24–29.Google Scholar
  25. 25.
    Polk HC Jr, Lopez-Mayor JF. Postoperative wound infection: a prospective study of determinant factors and prevention. Surgery (St. Louis) 1969;66:97–103.PubMedGoogle Scholar
  26. 26.
    Nichols RL, Webb WR, Jones JW, Smith JW, LoCicero J III. Efficacy of antibiotic prophylaxis in high risk gastroduodenal operations. Am J Surg 1982;143:94–98.PubMedCrossRefGoogle Scholar
  27. 27.
    Bold RJ, Mansfield PF, Berger DH, et al. Prospective, randomized, double-blind study of prophylactic antibiotics in axillary lymph node dissection. Am J Surg 1998;176:239–243.PubMedCrossRefGoogle Scholar
  28. 28.
    Gonzalez RP, Holevar MR. Role of prophylactic antibiotics for tube thoracostomy in chest trauma. Am Surg 1998;64:617–621.PubMedGoogle Scholar
  29. 29.
    Midtvedt K, Hartmann A, Midtvedt T, Brekke IB. Routine perioperative antibiotic prophylaxis in renal transplantation. Nephrol Dial Transplant 1998;13:1637–1641.PubMedCrossRefGoogle Scholar
  30. 30.
    Dobay KJ, Freier DT, Albear P. The absent role of prophylactic antibiotics in low-risk patients undergoing laparoscopic cholecystectomy. Am Surg 1999;65:226–228.PubMedGoogle Scholar
  31. 31.
    Dellinger EP, Gross PA, Barrett TL, et al. Quality standard for antimicrobial prophylaxis in surgical procedures. The Infectious Diseases Society of America. Infect Control Hosp Epidemiol 1994;15:182–188.PubMedGoogle Scholar
  32. 32.
    Piatt R, Zaleznik DF, Hopkins CC, et al. Perioperative antibiotic prophylaxis for herniorrhaphy and breast surgery. N Engl J Med 1990;322:153–160.Google Scholar
  33. 33.
    Classen DC, Evans RS, Pestonik SL, Horn SD, Menlove RL, Burke JP. The timing of prophylactic administration of antibiotics and the risk of surgical-wound infection. N Engl J Med 1992;326:281–286.PubMedGoogle Scholar
  34. 34.
    Bartlett JG, Condon RE, Gorbach SL, Clarke JS, Nichols RL, Ochi S. Veterans Administration Cooperative Study on Bowel Preparation for Elective Colorectal Operations: impact of oral antibiotic regimen on colonic flora, wound irrigation cultures and bacteriology of septic complications. Ann Surg 1978;188:249–254.PubMedCrossRefGoogle Scholar
  35. 35.
    Sawyer MD, Dunn DL. Antimicrobial therapy of intra-abdominal sepsis. Infect Dis Clin North Am 1992;6:545–570.PubMedGoogle Scholar
  36. 36.
    Nichols RL, Smith JW, Garcia RY, Waterman RS, Holmes JW. Current practices of preoperative bowel preparation among North American colorectal surgeons. Clin Infect Dis 1997;24:609–619.PubMedGoogle Scholar
  37. 37.
    Dunn DL. Gram-negative bacterial sepsis and sepsis syndrome. Surg Clin North Am 1994;74:621–635.PubMedGoogle Scholar
  38. 38.
    Bone RC, Balk RA, Cerra FB, et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 1992;101:1644–1655.PubMedCrossRefGoogle Scholar
  39. 39.
    Bossink AW, Groeneveld J, Hack CE, Thijs LG. Prediction of mortality in febrile medical patients: how useful are systemic inflammatory response syndrome and sepsis criteria? Chest 1998;113:1533–1541.PubMedCrossRefGoogle Scholar
  40. 40.
    Burd RS, Cody CS, Dunn DL. Immunotherapy of Gram-Negative Bacterial Sepsis. Austin, TX: Landes, 1992.Google Scholar
  41. 41.
    Dunn DL. Endotoxin antagonism. In: Baue AE, Faist E, Fry DE, eds. Multiple Organ Failure: Pathophysiology, Prevention, and Therapy. New York: Springer-Verlag, 2000.Google Scholar
  42. 42.
    Bodey G, Abi-Said D, Rolston K, Raad I, Whimbey E. Imipenem or cefoperazone-sulbactam combined with vancomycin for therapy of presumed or proven infection in neutropenic cancer patients. Eur J Clin Microbiol Infect Dis 1996;15:625–634.PubMedCrossRefGoogle Scholar
  43. 43.
    Hathorn JW, Lyke K. Empirical treatment of febrile neutropenia: evolution of current therapeutic approaches. Clin Infect Dis 1997;24:S256–S265.PubMedGoogle Scholar
  44. 44.
    Gross PA, Barrett TL, Dellinger EP, et al. Quality standard for the treatment of bacteremia. The Infectious Diseases Society of America. Infect Control Hosp Epidemiol 1994;15:189–192.PubMedCrossRefGoogle Scholar
  45. 45.
    Rex JH, Bennett JE, Sugar AM, et al. A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. Candidemia Study Group and the National Institute. N Engl J Med 1994;331:1325–1330.PubMedCrossRefGoogle Scholar
  46. 46.
    Goodman JL, Winston DJ, Greenfield RA, et al. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med 1992;326:845–851.PubMedGoogle Scholar
  47. 47.
    Ziegler EJ, Fisher CJ Jr, Sprung CL, et al. Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. A randomized, double-blind, placebo-controlled trial. The HA-1A Sepsis Study Group. N Engl J Med 1991;324:429–436.PubMedGoogle Scholar
  48. 48.
    Greenman RL, Schein RM, Martin MA, et al. A controlled clinical trial of E5 murine monoclonal IgM antibody to endotoxin in the treatment of gram-negative sepsis. JAMA 1991;266:1097–1102.PubMedCrossRefGoogle Scholar
  49. 49.
    McCloskey RV, Straube RC, Sanders C, Smith SM, Smith CR. Treatment of septic shock with human monoclonal antibody HA-1A. A randomized, double-blind, placebo-controlled trial. CHESS Trial Study Group. Ann Intern Med 1994;121:1–5.PubMedGoogle Scholar
  50. 50.
    Bone RC, Balk RA, Fein AM, et al. A second large controlled clinical study of E5, a monoclonal antibody to endotoxin: results of a prospective, multicenter, randomized, controlled trial. The E5 Sepsis Study Group. Crit Care Med 1995;23:994–1005.PubMedCrossRefGoogle Scholar
  51. 51.
    Abraham E, Wunderink R, Silverman H, et al. Efficacy and safety of monoclonal antibody to human tumor necrosis factor-oc in patients with sepsis syndrome. JAMA 1995;273:934–941.PubMedCrossRefGoogle Scholar
  52. 52.
    Fisher CJ Jr, Slotman GJ, Opal SM, et al. Initial evaluation of human recombinant interleukin-1 receptor antagonist in the treatment of sepsis syndrome: a randomized, open-label, placebo-controlled multicenter trial. The IL-1RA Sepsis Syndrome Study Group. Crit Care Med 1994;22:12–21.PubMedCrossRefGoogle Scholar
  53. 53.
    Fisher CJ Jr, Dhainaut JF, Opal SM, et al. Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebo-controlled trial. Phase III rhIL-1ra Sepsis Syndrome Study Group. JAMA 1994;271:1836–1843.PubMedCrossRefGoogle Scholar
  54. 54.
    Fisher CJ Jr, Agosti JM, Opal SM, et al. Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein. The Soluble TNF Receptor Sepsis Study Group. N Engl J Med 1996;334:1697–1702.PubMedCrossRefGoogle Scholar
  55. 55.
    Abraham E, Glauser MP, Butler T, et al. A p55 tumor necrosis factor receptor fusion protein in the treatment of patients with severe sepsis and septic shock. A randomized controlled multicenter trial. Ro 45-2081 Study Group. JAMA 1997;277:1531–1538.PubMedCrossRefGoogle Scholar
  56. 56.
    Bullard KM, Dunn DL. Diagnosis and treatment of bacteremia and intravascular catheter infections. Am J Surg 1996;172:S13–S19.CrossRefGoogle Scholar
  57. 57.
    Andrivet P, Bacquer A, Ngoc CV, et al. Lack of clinical benefit from subcutaneous tunnel insertion of central venous catheters in immunocompromised patients. Clin Infect Dis 1994;18:34–36.Google Scholar
  58. 58.
    Cobb D, High KP, Sawyer RG, et al. A controlled trial of scheduled replacement of central venous and pulmonary-artery catheters. N Engl J Med 1992;327:1062–1068.PubMedGoogle Scholar
  59. 59.
    Lim SH, Smith MP, Machin SJ, Goldstone AH. A prospective randomized study of prophylactic teicoplanin to prevent early Hickman-catheter-related sepsis in patients receiving intensive chemotherapy for haematological malignancies. Eur J Haematol 1993;54:10–13.Google Scholar
  60. 60.
    Maki DG, Stolz SM, Wheeler S, Mermel LA. Prevention of central venous catheter-related bloodstream infection by use of an antiseptic-impregnated catheter. A randomized, controlled trial. Ann Intern Med 1997;127:257–266.PubMedGoogle Scholar
  61. 61.
    Raad I, Darouiche R, Dupuis J, et al. Central venous catheters coated with minocycline and rifampin for the prevention of catheter-related colonization and bloodstream infections. A randomized, double-blind trial. The Texas Medical Center Catheter Study Group. Ann Intern Med 1997;127:267–274.PubMedGoogle Scholar
  62. 62.
    Darouiche RO, Raad II, Heard SO, et al. A comparison of two antimicrobial-impregnated central venous catheters. Catheter Study Group. N Engl J Med 1999;340:1–8.PubMedCrossRefGoogle Scholar
  63. 63.
    Collignon PJ. Intravascular catheter associated sepsis: a common problem. The Australian Study on Intravascular Catheter Associated Sepsis. Med J Aust 1994;161:374–378.PubMedGoogle Scholar
  64. 64.
    Martinez E, Mensa J, Rovira M, et al. Central venous catheter exchange by guidewire for treatment of catheter-related bacteraemia in patients undergoing BMT or intensive chemotherapy. Bone Marrow Transplant 1999;23:41–44.PubMedCrossRefGoogle Scholar
  65. 65.
    Raad I, Bompart F, Hachem R. Prospective, randomized dose-ranging open phase II pilot study of quinupristin/dalfopristin versus vancomycin in the treatment of catheter-related staphylococcal bacteremia. Eur J Clin Microbiol Infect Dis 1999;18:199–202.PubMedCrossRefGoogle Scholar
  66. 66.
    Johnson DC, Johnson FL, Goldman S. Preliminary results treating persistent venous catheter infections with the antibiotic lock technique in pediatric patients. Pediatr Infect Dis 1994;13:930–931.CrossRefGoogle Scholar
  67. 67.
    Henke PK, Bergamini TM, Rose SM, Richardson JD. Current options in prosthetic vascular graft infection. Am Surg 1998;64:39–45.PubMedGoogle Scholar
  68. 68.
    Sladen JG, Chen JC, Reid JD. An aggressive local approach to vascular graft infection. Am J Surg 1998;176:222–225.PubMedCrossRefGoogle Scholar
  69. 69.
    O’Brien T, Collin J. Prosthetic vascular graft infection. Br J Surg 1992;79:1262–1267.PubMedCrossRefGoogle Scholar
  70. 70.
    Reardon MJ, Vinnerkvist A, LeMaire SA. Mitral valve homograft for mitral valve replacement in acute bacterial endocarditis. J Heart Valve Dis 1999;8:71–73.PubMedGoogle Scholar
  71. 71.
    Dunn DL, Sawyer MD. Deep soft tissue infections. Curr Opin Infect Dis 1990;3:691–696.CrossRefGoogle Scholar
  72. 72.
    Bilton BD, Zibari GB, McMillan RW, Aultman DF, Dunn G, McDonald JC. Aggressive surgical management of necrotizing fasciitis serves to decrease mortality: a retrospective study. Am Surg 1998;64:397–400.PubMedGoogle Scholar
  73. 73.
    Sawyer MD, Dunn DL. Deep soft tissue infections. Curr Opin Infect Dis 1991;4:649–654.CrossRefGoogle Scholar
  74. 74.
    Sawyer MD, Dunn DL. Serious bacterial infections of the skin and soft tissues. Curr Opin Infect Dis 1995;8:293–297.CrossRefGoogle Scholar
  75. 75.
    Stamenkovic I, Lew DP. Early recognition of potentially fatal necrotizing fasciitis. The use of frozen-section biopsy. N Engl J Med 1984;310:1689–1696.PubMedGoogle Scholar
  76. 76.
    Stone HH, Martin JD. Synergistic necrotizing cellulitis. Ann Surg 1972;175:702–711.PubMedCrossRefGoogle Scholar
  77. 77.
    Riseman JA, Zamboni WA, Curtis A, Graham DR, Konrad HR, Ross DS. Hyperbaric oxygen therapy for necrotizing fasciitis reduces mortality and the need for debridements. Surgery (St. Louis) 1990;108:847–850.Google Scholar
  78. 78.
    Brown DR, Davis NL, Lepawsky M, Cunningham J, Kortbeek J. A multicenter review of the treatment of major truncal necrotizing infections with and without hyperbaric oxygen therapy. Am J Surg 1994;167:485–489.PubMedCrossRefGoogle Scholar
  79. 79.
    Topper SM, Plaga BR, Burner WL. Necrotizing myonecrosis and polymicrobial sepsis. The role of adjunctive hyperbaric oxygen. Orthop Rev 1990;14:895–900.Google Scholar
  80. 80.
    Hall RL, Callaghan JJ, Moloney E, Martinez S, Harrelson JM. Pyomyositis in a temperate climate. Presentation, diagnosis, and treatment. J Bone Joint Surg 1990;72:1240–1244.PubMedGoogle Scholar
  81. 81.
    Dunn DL, Simmons RL. The role of anaerobic bacteria in intraabdominal infections. Rev Infect Dis 1984;6:S139–S146.PubMedGoogle Scholar
  82. 82.
    Nichols RL, Smith JW, Klein DB, et al. Risk of infection after penetrating abdominal trauma. N Engl J Med 1984;311:1065–1070.PubMedCrossRefGoogle Scholar
  83. 83.
    Dellinger EP, Wertz MJ, Lennard ES, Oreskovich MR. Efficacy of short-course antibiotic prophylaxis after penetrating intestinal injury. A prospective randomized trial. Arch Surg 1986;121:23–30.PubMedGoogle Scholar
  84. 84.
    Bohnen J, Boulanger M, Meakins JL, McLean AP. Prognosis in generalized peritonitis. Relation to cause and risk factors. Arch Surg 1983;118:285–290.PubMedGoogle Scholar
  85. 85.
    Dunn DL, Simmons RL. Anaerobic microorganisms in intra-abdominal infection: significance and treatment. In: Simmons RL, ed. Topics in Intraabdominal Surgical Infection, Vol. 2. New York: Appleton Century Crofts, 1984:1–16.Google Scholar
  86. 86.
    Solomkin JS, Dellinger EP, Christou NV, Busuttil RW. Results of a multicenter trial comparing imipenem/cilastatin to tobramycin/clindamycin for intra-abdominal infections. Ann Surg 1990;212:581–591.PubMedCrossRefGoogle Scholar
  87. 87.
    Bohnen JM, Solomkin JS, Dellinger EP, Bjornson HS, Page CP. Guidelines for clinical care: anti-infective agents for intra-abdominal infection. A Surgical Infection Society policy statement. Arch Surg 1992;127:83–89.PubMedGoogle Scholar
  88. 88.
    Christou NV, Barie PS, Dellinger EP, Waymack JP, Stone HH. Surgical Infection Society intra-abdominal infection study. Prospective evaluation of management techniques and outcome. Arch Surg 1993;128:193–198.PubMedGoogle Scholar
  89. 89.
    Condon RE, Walker AP, Sirinek KR, et al. Meropenem versus tobramycin plus clindamycin for treatment of intraabdominal infections: results of a prospective, randomized, double-blind clinical trial. Clin Infect Dis 1995;21:544–550.PubMedGoogle Scholar
  90. 90.
    Barie PS, Vogel SB, Dellinger EP, et al. A randomized, double-blind clinical trial comparing cefepime plus metronidazole with imipenem-cilastatin in the treatment of complicated intra-abdominal infections. Cefepime Intra-abdominal Infection Study Group. Arch Surg 1997;132:1294–1302.PubMedGoogle Scholar
  91. 91.
    Solomkin JS, Reinhart HH, Dellinger EP, et al. Results of a randomized trial comparing sequential intravenous/oral treatment with ciprofloxacin plus metronidazole to imipenem/cilastatin for intra-abdominal infections. The Intra-Abdominal Infection Study Group. Ann Surg 1996;223:303–315.PubMedCrossRefGoogle Scholar
  92. 92.
    Stone HH, Bourneuf AA, Stinson LD. Reliability of criteria for predicting persistent or recurrent sepsis. Arch Surg 1985;120:17.PubMedGoogle Scholar
  93. 93.
    Lennard ES, Dellinger EP, Wertz MJ, et al. Implications of leukocytosis and fever at conclusion of antibiotic therapy for intra-abdominal sepsis. Ann Surg 1982;195:19.PubMedCrossRefGoogle Scholar
  94. 94.
    Mosdell DM, Morris DM, Voltura A, et al. Antibiotic treatment for surgical peritonitis. Ann Surg 1991;214:543–549.PubMedCrossRefGoogle Scholar
  95. 95.
    Rotstein OD, Pruett TL, Simmons RL. Microbiologic features and treatment of persistent peritonitis in patients in the intensive care unit. Can J Surg 1986;29:247.PubMedGoogle Scholar
  96. 96.
    Berne TV, Yellin AW, Appleman MD, Heseltine PNR. Antibiotic management of surgically treated gangrenous or perforated appendicitis. Comparison of gentamicin and clindamycin versus cefamandole versus cefoperazone. Am J Surg 1982;144:8–13.PubMedCrossRefGoogle Scholar
  97. 97.
    Heseltine PNR, Yellin AE, Appleman MD, et al. Imipenem therapy for perforated and gangrenous appendicitis. Surg Gynecol Obstet 1986;162:43–48.PubMedGoogle Scholar
  98. 98.
    Berne TV, Yellin A, Appleman MD, Gill MA, Chenella FC, Heseltine PNR. Surgically treated gangrenous or perforated appendicitis. A comparison of aztreonam and clindamycin versus gentamicin and clindamycin. Ann Surg 1987;205:133–137.PubMedCrossRefGoogle Scholar
  99. 99.
    Bauer R, Vennits B, Holm B, et al. Antibiotic prophylaxis in acute nonperforated appendicitis. The Danish multicenter study group 111. Ann Surg 1989;209:307–311.PubMedCrossRefGoogle Scholar
  100. 100.
    Solomkin JS, Flohr AB, Quie PG, Simmons RL. The role of Candida in intraperitoneal infections. Surgery (St. Louis) 1980;88:524–530.Google Scholar
  101. 101.
    Powderly WG, Saag MS, Cloud GA, et al. A controlled trial of fluconazole or amphotericin B to prevent relapse of cryptococcal meningitis in patients with the acquired immunodeficiency syndrome. The NIAID AIDS Clinical Trials Group and Mycoses Study Group. N Engl J Med 1992;326:793–798.PubMedGoogle Scholar
  102. 102.
    Morrison VA, Peterson BA, Dunn DL. Post-transplant lympho-proliferative disorders: pathogenesis, presentation, and approaches to therapy. In: Faist E, Baue AE, Schildber FW, eds. The Immune Consequences of Trauma, Shock and Sepsis—Mechanisms and Therapeutic Approaches. Berlin: Pabst, 1996:592–602.Google Scholar
  103. 103.
    Dunn DL, Mayoral JL, Gillingham KJ, et al. Treatment of invasive cytomegalovirus disease in solid organ transplant patients with ganciclovir. Transplantation 1991;51:98–106.PubMedCrossRefGoogle Scholar
  104. 104.
    Dunn DL, Gillingham KJ, Kramer MA, et al. A prospective randomized study of acyclovir versus ganciclovir plus human immune globulin prophylaxis of cytomegalovirus infection after solid organ transplantation. Transplantation 1994;57:876–884.PubMedGoogle Scholar
  105. 105.
    Snydman DR, Werner BG, Heinze-Lacey B. Use of cytomegalovirus immune globulin to prevent cytomegalovirus disease in renal-transplant recipients. N Engl J Med 1987;317:1049–1054.PubMedGoogle Scholar
  106. 106.
    Balfour HH, Chace BA, Stapleton JT. A randomized, placebo-controlled trial of oral acyclovir for the prevention of cytomegalovirus disease in recipients of renal allografts. N Engl J Med 1989;320:1381–1385.PubMedGoogle Scholar
  107. 107.
    Lowance D, Neumayer HH, Legendre CM, et al. Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. International Valacyclovir Cytomegalovirus Prophylaxis Transplantation Study Group. N Engl J Med 1999;340:1462–1470.PubMedCrossRefGoogle Scholar
  108. 108.
    Sharma MP, Dasarathy S. Amoebic liver abscess. Trop Gastroenterol 1993;14:3–9.PubMedGoogle Scholar
  109. 109.
    Di Matteo G, Bove A, Chiarini S, et al. Hepatic echinococcus disease: our experience over 22 years. Hepato-Gastroenterology 1996;43:1562–1565.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2008

Authors and Affiliations

  • David L. Dunn
    • 1
  1. 1.Department of SurgeryUniversity at Buffalo/SUNYBuffaloUSA

Personalised recommendations